Paradigm Biopharmaceuticals Limited

ASX:PAR Stock Report

Market Cap: AU$131.0m

Paradigm Biopharmaceuticals Valuation

Is PAR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PAR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PAR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PAR's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PAR?

Key metric: As PAR is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for PAR. This is calculated by dividing PAR's market cap by their current book value.
What is PAR's PB Ratio?
PB Ratio5.5x
BookAU$23.81m
Market CapAU$131.04m

Price to Book Ratio vs Peers

How does PAR's PB Ratio compare to its peers?

The above table shows the PB ratio for PAR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average6.4x
DXB Dimerix
9.7xn/aAU$175.7m
CYP Cynata Therapeutics
5x72.9%AU$36.1m
BTG Beroni Group
8.7xn/aAU$75.9m
IMU Imugene
2.4x53.4%AU$282.6m
PAR Paradigm Biopharmaceuticals
5.5x-13.2%AU$131.0m

Price-To-Book vs Peers: PAR is good value based on its Price-To-Book Ratio (5.5x) compared to the peer average (5.7x).

Price to Book Ratio vs Industry

How does PAR's PB Ratio compare vs other companies in the AU Biotechs Industry?

1 CompanyPrice / BookEstimated GrowthMarket Cap
BNO Bionomics
0.3x-36.0%US$9.52m
No more companies available in this PB range
PAR 5.5xIndustry Avg. 2.9xNo. of Companies5PB0246810+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: PAR is expensive based on its Price-To-Book Ratio (5.5x) compared to the Australian Biotechs industry average (2.9x).

Price to Book Ratio vs Fair Ratio

What is PAR's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PAR PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio5.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate PAR's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PAR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$0.38
AU$0.85
+128.0%
6.4%AU$0.91AU$0.80n/a2
Dec ’25AU$0.52
AU$0.85
+66.0%
6.4%AU$0.91AU$0.80n/a2
Nov ’25AU$0.20
AU$0.69
+236.6%
31.9%AU$0.91AU$0.47n/a2
Oct ’25AU$0.20
AU$0.69
+253.8%
31.9%AU$0.91AU$0.47n/a2
May ’25AU$0.28
AU$2.30
+705.3%
39.0%AU$3.19AU$1.40n/a2
Apr ’25AU$0.34
AU$2.30
+565.2%
39.0%AU$3.19AU$1.40n/a2
Mar ’25AU$0.34
AU$2.30
+585.1%
39.0%AU$3.19AU$1.40n/a2
Feb ’25AU$0.32
AU$2.30
+628.6%
39.0%AU$3.19AU$1.40n/a2
Jan ’25AU$0.42
AU$2.30
+440.0%
39.0%AU$3.19AU$1.40n/a2
Dec ’24AU$0.40
AU$2.30
+481.0%
39.0%AU$3.19AU$1.40AU$0.522
Nov ’24AU$0.41
AU$2.30
+453.0%
39.0%AU$3.19AU$1.40AU$0.202
Oct ’24AU$0.61
AU$2.70
+338.2%
18.4%AU$3.19AU$2.20AU$0.202
Sep ’24AU$0.66
AU$2.70
+308.3%
18.4%AU$3.19AU$2.20AU$0.242
Aug ’24AU$0.91
AU$2.70
+194.5%
18.4%AU$3.19AU$2.20AU$0.262
Jul ’24AU$0.99
AU$2.70
+172.2%
18.4%AU$3.19AU$2.20AU$0.292
Jun ’24AU$0.83
AU$2.70
+222.8%
18.4%AU$3.19AU$2.20AU$0.252
May ’24AU$1.00
AU$2.70
+169.5%
18.4%AU$3.19AU$2.20AU$0.282
Apr ’24AU$1.43
AU$2.70
+87.8%
18.4%AU$3.19AU$2.20AU$0.342

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 08:46
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Paradigm Biopharmaceuticals Limited is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John HesterBell Potter
Soo RomanoffEdison Investment Research
Arron AatkarEdison Investment Research